Sanofi says rare lung disease drug outperforms standard care in trial

Sanofi said a trial showed its rare disease therapy outperformed standard care in raising levels of a key protein in patients with a genetic form of lung disease. The result is clinically encouraging for the drug’s development and supports the therapy’s efficacy profile. The news is positive for Sanofi, though the article provides no data on statistical significance, safety, or commercial impact.

Analysis

Sanofi said a trial showed its rare disease therapy outperformed standard care in raising levels of a key protein in patients with a genetic form of lung disease. The result is clinically encouraging for the drug’s development and supports the therapy’s efficacy profile. The news is positive for Sanofi, though the article provides no data on statistical significance, safety, or commercial impact.